Opendata, web and dolomites

PARPinhibit SIGNED

A systems biology approach to tackle PARP-inhibitors resistance and identify novel therapeutic targets to overcome it

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PARPinhibit" data sheet

The following table provides information about the project.

Coordinator
CONSIGLIO NAZIONALE DELLE RICERCHE 

Organization address
address: PIAZZALE ALDO MORO 7
city: ROMA
postcode: 185
website: www.cnr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 251˙002 €
 EC max contribution 251˙002 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-GF
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) coordinator 251˙002.00
2    H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC US (TAMPA FL) partner 0.00

Map

 Project objective

Inhibition of PARP1 in cancer therapy is a recently adopted strategy to treat cancers where DNA repair is defective, such as breast and ovarian cancer caused by mutations in BRCA1 or BRCA2. In addition, PARP1 inhibitors (PARPi) can be useful even in the absence of BRCA mutations, likely due to pathogenic variants or epigenetic inactivation of other DNA repair related genes. However, development of resistance to PARPi is a significant challenge. To address this challenge, I propose to identify proteins that modulate PARP1 activity that could be used as additional therapeutic targets. The strength of this project is based on a systems biology overall strategy exploiting multiple independent datasets to identify candidates protein interactors, followed by a rigorous biochemical and genetic approach to characterize this interaction. Analysis of identified proteins and their role in PARPi resistance will be achieved at three main levels: a) in-silico and molecular studies of the interaction; b) influence on PARP1 activity and role in PARPi resistance after CRISPR-cas9 editing; c) expression levels in breast and ovarian cancer tissues. Results from this project will illuminate mechanisms of PARPi resistance and generate potential targets for therapy in breast and ovarian cancer. These results will contribute to the reduction in mortality due to breast and ovarian cancer and they will give an answer to this world-wide diffuse challenge.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PARPINHIBIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PARPINHIBIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

Long-term migration (2019)

Immigration, Attitudes of Natives and Immigrants Assimilation

Read More